SEC Form 4 · accession 0001209191-17-058085
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Happel
Officer — EVP, Commercial Dev & Strategy
Period of report
Oct 25, 2017
Accepted (ET)
Oct 26, 2017 · 7:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Oct 25, 2017 | M | 7,953 | — | A | 9,239 | D | |
| Ordinary Shares | Oct 25, 2017 | F | 4,150 | $13.53 | D | 5,089 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Oct 25, 2017 | M | 7,953 | D | — | — | Ordinary Shares | 7,953 | 23,860 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- F2Includes 1,286 ordinary shares of the Issuer acquired by the reporting person on June 1, 2017 pursuant to an employee stock purchase program.
- F3On October 25, 2016, the reporting person was granted an aggregate of 31,813 restricted stock units. The restricted stock units vest in four equal annual installments beginning on October 25, 2017.